Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications
Journal of Wound Care · 2025
DOI: 10.12968/jowc.2021.0365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Wound Care, 2025. Verfasst von Pelin Esme und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Health Sciences, Gulhane Training and Research Hospital, Department of Dermatology and Venereology, Ankara, Turkey. Hauptthemen laut MEDLINE: Adalimumab, Hidradenitis Suppurativa, Wound Healing, Postoperative Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Wundversorgung
Abstract (Originalsprache)
Objective
The combination of adalimumab and surgical interventions plays a crucial role in managing severe hidradenitis suppurativa (HS). However, there is still limited scientific evidence regarding administering adalimumab during the perioperative period. This study aimed to evaluate whether adalimumab could adversely affect postoperative complications and the total time of wound closure (TTWC) in patients undergoing cutaneous surgery for HS.
Method
In this single-centre cohort study, patients with HS were allocated to two groups. Group 1 (biological cohort) consisted of patients with HS who had continuously received adalimumab for at least three months before the procedure. Group 2 (non-biological cohort) patients underwent cutaneous surgery after only four weeks of anti-inflammatory medication. All patients were left to secondary wound healing.
Results
A total of 30 surgical sites in 20 patients were included in the study (Group 1: 15 surgical sites/nine patients; Group 2: 15 surgical sites/11 patients). Disease severity and excised skin areas were significantly higher in Group 1 (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Health Sciences, Gulhane Training and Research Hospital, Department of Dermatology and Venereology, Ankara, Turkey.
Zitieren
APA
Esme, P., Botsali, A., & Caliskan, E. (2025). Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications. Journal of Wound Care. https://doi.org/10.12968/jowc.2021.0365
Vancouver
Esme P, Botsali A, Caliskan E. Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications. Journal of Wound Care. 2025. doi:10.12968/jowc.2021.0365
BibTeX
@article{Esme2025,
author = {Esme, Pelin and Botsali, Aysenur and Caliskan, Ercan},
title = {Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications},
journal = {Journal of Wound Care},
year = {2025},
doi = {10.12968/jowc.2021.0365}
}
EUVIMED